Menu
← Oncology Approval Tracker
FDA DECISION ·
Rezurock
belumosudil · Kadmon Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children age 12 and older with chronic graft-versus-host disease after failure of at least two prior systemic treatment lines.
LAMPGEN ANALYSIS
Why it matters
The approval adds a ROCK2 inhibitor for refractory post-transplant disease.
What research teams should watch
Document prior systemic treatments and baseline organ involvement before following response.
PRIMARY RECORDS